Issues in the meta-analysis of cluster randomized trials.
about
Nidotherapy for people with schizophreniaPsychosocial interventions for self-harm in adultsChlorpromazine versus reserpine for schizophreniaRisperidone (depot) for schizophreniaChlorpromazine versus atypical antipsychotic drugs for schizophreniaYoga as part of a package of care versus standard care for schizophreniaDietary advice for people with schizophreniaChlorpromazine versus reserpine for schizophreniaAcetylsalicylic acid (aspirin) for schizophreniaClozapine augmentation for treatment-resistant schizoaffective disorderAripiprazole versus haloperidol for people with schizophrenia and schizophrenia-like psychosesAripiprazole versus chlorpromazine for people with schizophrenia and schizophrenia-like psychosesAripiprazole versus sulpiride for people with schizophrenia and schizophrenia-like psychosesAripiprazole versus perphenazine for people with schizophrenia and schizophrenia-like psychosesLithium for schizophreniaSmoking cessation advice for people with serious mental illnessNon-drug conservative treatments for acute urinary retention after surgery in adultsCognitive behavioural therapy (brief versus standard duration) for schizophreniaYoga versus standard care for schizophreniaSupportive therapy for schizophreniaPharmacological interventions for self-harm in adultsPsychoeducation (brief) for people with serious mental illnessAntiglucocorticoid and related treatments for psychosisMammario-arterial anastomosis versus aorto-arterial anastomosis as proximal anastomotic sites in coronary artery bypass surgery for patients with multivessel diseaseYoga versus non-standard care for schizophreniaIncreasing antipsychotic dose for non response in schizophreniaIncreasing antipsychotic dose versus switching antipsychotic for non response in schizophreniaBifeprunox versus placebo for schizophreniaAmphetamines versus placebo for schizophreniaAcetophenazine versus chlorpromazine for schizophreniaPsychological interventions for post-traumatic stress disorder (PTSD) in people with severe mental illnessPharmacological interventions for benzodiazepine discontinuation in chronic benzodiazepine usersTai chi for schizophreniaCalcium channel blockers for preventing cardiomyopathy due to iron overload in people with transfusion-dependent beta thalassaemia'As required' medication regimens for seriously mentally ill people in hospitalAsenapine versus placebo for schizophreniaInterventions for self-harm in children and adolescentsSocial skills programmes for schizophreniaCrisis intervention for people with severe mental illnessesAngiotensin-converting enzyme (ACE) inhibitors for proteinuria and microalbuminuria in people with sickle cell disease
P2860
Q22252963-B1099BBF-AC27-43B8-897A-BC2CA71E6E98Q24185772-1B7BF349-B309-4D06-9882-9CF7DE93C881Q24185855-A757E719-2ECD-49EE-9164-B10FFDE99E8CQ24185901-8BB98103-2A6A-47AE-B2CD-934312906AE9Q24185922-7F27AB62-2986-4B1A-A94B-44A39F08CD7BQ24185976-5730A9F4-F7EF-4AE1-A638-4D9F9920A7C8Q24186009-3414C53C-4DDB-4A4B-861B-C151F09A458BQ24186067-5F8143C7-5D0A-4D6B-9F29-EDD68114743DQ24186077-6F45BD99-0D4F-42A9-B87A-CB2F87AFDD81Q24186084-EBF76898-914B-4DB1-8DA4-CD77DAAA4C36Q24186218-067487A9-86C2-4EAE-B035-D146F5E93CECQ24186219-4206AD90-16C9-425C-81AD-78310034C9DFQ24186220-6F4977C7-0803-484F-B19F-77B8BB98889DQ24186223-6FA00BBA-34B5-4D2A-BCA8-6F6D3CA05DD1Q24186325-CEDC75D1-CF15-4D4E-AA00-29DA81C6F04BQ24186349-BBDD9381-7A9D-4803-B351-30C9DE6D917DQ24186354-28DF6446-E689-4ED2-938B-14642DEC720FQ24186426-B61B0257-0EC1-4A59-8A25-278B682749D3Q24186431-31787914-C5D9-4686-9952-F0C22D326327Q24186517-674EC706-2F4D-44B5-8201-93FE7D177FE8Q24186543-2E211D4F-0E9F-40EF-98BD-C48C4C325166Q24186564-B2AB5123-8CF7-4FBB-AB61-0F3B871D0386Q24186594-3D3B4DFF-695E-43C9-B0C3-E949AE154ADAQ24186682-638E1607-DA07-4D6E-9BD3-6B3395D96F59Q24186727-CA5DAAC6-2C6C-4E40-A7A7-E763AA44B8BDQ24186768-809FF68C-80AD-49EE-9AFD-7A0C8E162DBAQ24186772-4F4F8679-7096-471B-A4B0-98AACA684E06Q24186774-B35F53A3-8669-4FC1-93B8-4F66FC934F24Q24186797-EA22FE64-4BB3-4BF2-B2DE-BA033507C5BAQ24186800-2F0AFA79-4A0E-4302-B1F3-61C20112B2B5Q24186868-C5F89C55-815D-4BAE-A53F-9CC9B89E6EE4Q24186909-5EDCDF0A-2364-4BEE-8576-C519ADAA21D2Q24186914-8FB392E4-3988-465F-969D-68E04FB31A2BQ24186957-954A98E6-9720-4B85-809D-D9C274224561Q24187005-32055AD8-437A-403F-8B67-39135071AEA2Q24187012-4379A5A9-733A-4AB0-A1E4-753999B44383Q24187033-A0C1C25D-3B48-43C0-BC94-62AE5956959AQ24187223-15A1F9E3-EBB6-433F-AAD6-48BD29A5A8EFQ24187228-A0E69C5B-403E-45B8-ADFF-4FDB06A9DC92Q24187284-88366909-DFF1-4506-88CB-8E6BE6F97EAF
P2860
Issues in the meta-analysis of cluster randomized trials.
description
2002 nî lūn-bûn
@nan
2002 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Issues in the meta-analysis of cluster randomized trials.
@ast
Issues in the meta-analysis of cluster randomized trials.
@en
Issues in the meta-analysis of cluster randomized trials.
@nl
type
label
Issues in the meta-analysis of cluster randomized trials.
@ast
Issues in the meta-analysis of cluster randomized trials.
@en
Issues in the meta-analysis of cluster randomized trials.
@nl
prefLabel
Issues in the meta-analysis of cluster randomized trials.
@ast
Issues in the meta-analysis of cluster randomized trials.
@en
Issues in the meta-analysis of cluster randomized trials.
@nl
P356
P1476
Issues in the meta-analysis of cluster randomized trials.
@en
P2093
Allan Donner
P304
P356
10.1002/SIM.1301
P407
P577
2002-10-01T00:00:00Z